NeuroSense Therapeutics Ltd.
NRSN
NASDAQ·Healthcare·Biotechnology·Mkt cap $18.1M
$0.51
▲ +27.19%
P/E
—
Mkt Cap
$18.1M
52-Wk Range
$0.25–$1.98
52-Week Range
$0.25 - $1.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 56.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral formulation technology platform reducing treatment barriers
- Advanced clinical data with Phase IIa completed trials for lead candidate
- Focused pipeline addressing large unmet medical needs in neurodegenerative diseases
- Strategic positioning in high-value pharmaceutical markets with limited competition
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Progression of PrimeC through clinical development toward Phase IIb/III trials
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-31.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NRSN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.03.
Reported EPS · last 4Q
Q2 25
-$0.03
Q1 25
-$0.03
Q4 24
-$0.03
Q3 24
-$0.04
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Sep 3, 2026
vs Industry
How NRSN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.